TITLE:
The Outcome of Treatment for Patients with Borrmann Type 4 Advanced Gastric Cancer
AUTHORS:
Rie Tamaki, Fumio Amano, Tohru Hashida, Hironaga Satake, Hisateru Yasui, Akihito Tsuji
KEYWORDS:
Gastric Cancer, Adenocarcinoma, Scirrhous, Cisplatin, Chemotherapy, Metastasis
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.12,
November
17,
2016
ABSTRACT: Introduction: The survival rate of patients with
Borrmann type 4 advanced gastric cancer is extremely poor in comparison to
patients with gastric
cancers of other histological types. An optimal chemotherapeutic regimen has
yet to be determined. Patients
and Methods: We retrospectively examined the outcome of patients who were
treated for Borrmann
type 4 advanced gastric cancer from
July 2011 and June 2015. Results:
The data from 42 cases were collected for this study. Of the 42 cases, 13 cases
(31.0%) were locally advanced and 29 cases (69.0%) were metastatic advanced.
Median Overall Survival (OS) for locally advanced cancer was 29.6 months and
for metastatic advanced cancer was 11.5 months. The presence or absence of
peritoneal metastases did not affect survival (8.9 and 11.5 months,
respectively; p = 0.831). In the 23 patients who received chemotherapy, S-1
plus cisplatin was
prescribed as first-line treatment in 16 cases (69.5%). Other treatment regimens included capecitabine plus
cisplatin and S-1 plus oxaliplatinin one each (4.3%), S-1 monotherapy in two
(8.6%), and capecitabine monotherapy, paclitaxel, and docetaxel in one each
(4.3%). We
found no median OS difference between S-1 plus cisplatin and other treatments
(20.7 and 19.3 months; p = 0.094). Conclusion: We found that S-1 plus cisplatin treatment does not improve OS in patients
with Borrmann type 4 advanced gastric cancer compared with other chemotherapeutic regimens.